Peptide Combinations Guide
Search “peptide stacking” and you'll find dozens of guides telling you which peptides to combine. Most are published by companies selling those exact peptides. This guide assesses combinations honestly, with evidence tiers, regulatory context and clear acknowledgment of what we know versus what we're guessing.
We don't sell peptides. We don't provide dosing protocols — that's your provider's job.
How We Evaluate Combinations
Three dimensions: mechanistic rationale (do they work through different pathways?), evidence for the pairing itself (individual compound data is not combination data) and regulatory reality (can you actually access both?).
Combination Evidence Tiers
Research has directly tested this combination and found the combined effect exceeds either compound alone. Rare.
Different biological pathways, practitioners prescribe with reported positive outcomes. No controlled trial on the specific combination.
Reasonable logic but newer, more limited clinical experience.
Recovery & Repair Combinations
“The Wolverine Stack”
BPC-157 works through growth factor modulation and angiogenesis locally. TB-500 works through actin regulation and stem cell mobilization systemically. Different pathways targeting tissue repair. No formal human trial on this combination.
The “wolverine” branding comes from biohacking culture, not clinical research. BPC-157 alone is often sufficient for a single localized injury. The combination is typically reserved for complex or stubborn injuries.
Both Category 2, expected Category 1.
Ask your provider: For my injury, would you start with one compound or recommend both?
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
BPC-157 + GHK-Cu
Tier B: Complementary MechanismsRepair + Collagen/Skin
Post-GLP-1 skin laxity is a growing concern. BPC-157 handles systemic healing; GHK-Cu promotes collagen synthesis and skin regeneration. Also used around laser treatments and microneedling.
Both Category 2, expected Category 1.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
Growth Hormone Optimization
CJC-1295 + Ipamorelin
Tier A: Synergy Studied“The Classic Stack”
One of the few peptide combinations with genuine clinical evidence. CJC-1295 stimulates GH through GHRH receptors. Ipamorelin triggers GH release through ghrelin receptors. 1999 research demonstrated simultaneous stimulation produces synergistic GH output — significantly greater than the sum of individual responses.
Unlike older secretagogues, Ipamorelin is highly selective — primarily stimulates GH without significantly elevating cortisol or prolactin.
Both PCAC-referred since September 2024.
Ask your provider: What are my baseline GH and IGF-1 levels? With or without DAC — and why?
CJC/Ipamorelin + BPC-157/TB-500
Tier B: Complementary MechanismsPerformance Recovery
GH optimization for systemic recovery plus repair peptides for tissue-level healing. Most common multi-peptide protocol for active adults 30–55. Individual mechanisms well-characterized but zero studies on this four-compound combination. Logical but unproven.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
Immune & Gut Health
Thymosin Alpha-1 + BPC-157
Tier B: Complementary MechanismsImmune + Gut Integrity
Thymosin Alpha-1 modulates systemic immune function through TLR signaling and T-cell maturation. BPC-157 addresses gut lining integrity. 70–80% of the immune system resides in the gut, so the pairing has strong biological logic. Used for post-viral immune recovery and chronic GI conditions.
Thymosin Alpha-1 is PCAC-referred. BPC-157 expected Category 1.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
BPC-157 + KPV
Tier C: Emerging / LimitedGut Healing + Anti-Inflammatory
KPV is a tripeptide with anti-inflammatory properties for bowel conditions. Combined with BPC-157's gut-healing effects, targets GI repair from two angles. Reasonable logic, minimal hard evidence.
Both Category 2, expected Category 1.
Weight Management
Semaglutide + CJC-1295/Ipamorelin
Tier B: Complementary MechanismsWeight Loss + Lean Mass Preservation
Semaglutide produces significant weight loss but research documents meaningful lean muscle mass loss. GH peptides promote lean mass retention during caloric deficit. Independent receptor systems, no pharmacological conflict expected. Sound rationale but no formal combination study.
As of April 2026, this combination involves an FDA-approved pharmaceutical (semaglutide — available only as branded Wegovy/Ozempic at $935–$1,349/month) with compounds that are Category 2 but expected to return to Category 1 (CJC/Ipa are PCAC-referred). Only makes sense under close physician supervision with both compounds obtained through legitimate channels.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
AOD-9604 + CJC-1295/Ipamorelin
Tier B: Complementary MechanismsFat Metabolism + GH Support
AOD-9604 is a modified GH fragment isolated for fat metabolism without broader hormonal effects.
All three PCAC-referred.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
Cognitive
Cognitive + Anxiety
Semax modulates BDNF and catecholamine systems (focus). Selank acts on GABAergic systems (anxiety reduction). Cognitive “gas” + emotional “brake.” Both approved pharmaceuticals in Russia with decades of use. Both nasal — no injection required.
Without controlled human trials, we can’t rule out that the perceived benefits are placebo, coincidental with other treatments or overstated by practitioners with financial incentive to prescribe.
Safety Principles
- Angiogenesis stacking: BPC-157 and TB-500 both promote new blood vessel formation. Cancer history requires oncologist discussion.
- GH + insulin: GH compounds affect blood sugar. Monitor glucose if combining with metabolic peptides.
- Blood pressure: BPC-157 interacts with the nitric oxide system. Inform provider about all medications.
- Pregnancy: Absolute contraindication across all pairings.
Red Flags in Combination Marketing
- Embedded purchase links in “educational” content — If a guide has buy buttons for the peptides it’s discussing, the incentive structure is compromised.
- Branded stack names with discount codes — “Wolverine Stack” is a marketing name, not a clinical term.
- Dosing protocols presented as instructions rather than ranges — Any source that tells you exactly what to inject without emphasizing that your provider determines dosing based on your individual health profile is optimizing for self-administration, not education.
- No evidence tiers — If every combination is presented with equal confidence, excitement is being prioritized over accuracy.
Only one combination in this guide (CJC-1295 + Ipamorelin) has formal data demonstrating synergistic effects. The rest range from strong mechanistic logic to pure theory. Consumers deserve to know which category their combination falls into. Bring this guide to your next consultation.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.